tiprankstipranks
Trending News
More News >
AnteoTech Ltd (AU:ADO)
ASX:ADO
Australian Market

AnteoTech Ltd (ADO) AI Stock Analysis

Compare
16 Followers

Top Page

AU:ADO

AnteoTech Ltd

(Sydney:ADO)

Select Model
Select Model
Select Model
Underperform 40 (OpenAI - 5.2)
Rating:40Underperform
Price Target:
AU$0.01
▼(-40.00% Downside)
The score is driven primarily by weak financial performance (ongoing losses, negative operating/free cash flow, and sharp revenue volatility). Technicals add further pressure with a clear downtrend (below major moving averages and negative MACD). Valuation is not supportive because the negative P/E reflects unprofitable operations and there is no dividend yield data.
Positive Factors
Proprietary materials and dual end-markets
AnteoTech’s proprietary coating and binding technologies address both diagnostics and lithium-ion battery markets. This dual end-market exposure creates multiple commercialization pathways and structural demand drivers, supporting long-term product adoption and partner-led scale.
Manageable leverage
A moderate 0.62 debt-to-equity ratio implies limited financial leverage compared with distressed peers, reducing near-term refinancing risk. This balance-sheet cushion gives the company more runway to fund commercialization, R&D and customer qualification without overreliance on urgent external capital.
High gross profit margin
High gross margins on materials/coatings suggest attractive unit economics once volumes scale. Durable gross profitability supports future operating leverage, enabling incremental revenues to flow to the bottom line faster if commercial uptake and manufacturing efficiencies improve.
Negative Factors
Persistent unprofitability
The company’s ongoing negative EBIT and EBITDA margins show it remains unprofitable at the operating level. Persistent losses limit internal funding for growth, increase dependence on external capital, and indicate structural cost or scale challenges that must be addressed for long-term sustainability.
Negative operating and free cash flow
Negative operating and free cash flows impair the firm’s ability to fund commercialization, capital expenditures and working capital from operations. Until OCF turns positive, the business faces ongoing financing needs that can dilute shareholders and constrain strategic flexibility.
Severe revenue volatility and recent decline
Large swings and a sharp recent drop in revenue undermine predictability of customer demand and complicate scaling. Volatility suggests commercial execution or market adoption issues that, if unresolved, will hamper sustainable margin improvement and long-term cash generation.

AnteoTech Ltd (ADO) vs. iShares MSCI Australia ETF (EWA)

AnteoTech Ltd Business Overview & Revenue Model

Company DescriptionAnteoTech Limited, a surface chemistry company, develops, commercializes, manufactures, and distributes products for the life sciences, diagnostics, energy, and medical device markets primarily in Australia. Its products include AnteoBind ready-to-use kits to streamline and enhance the conjugation process; AnteoX, an additive that reinforces battery binders helping maximize performance of silicon containing anodes; EuGeni, a COVID-19 antigen rapid test; and AnteoRelease and AnteoCoat. The company was formerly known as Anteo Diagnostics Limited and changed its name to AnteoTech Limited in November 2019. AnteoTech Limited is headquartered in Eight Mile Plains, Australia.
How the Company Makes MoneyAnteoTech generates revenue primarily through the commercialization of its proprietary technology and products in the diagnostics and medical device markets. Key revenue streams include licensing agreements with other companies that utilize AnteoTech's technology in their products, direct sales of its diagnostic solutions, and research and development partnerships with healthcare organizations and research institutions. Additionally, AnteoTech may benefit from grants and funding aimed at supporting biotechnological innovations, further contributing to its earnings.

AnteoTech Ltd Financial Statement Overview

Summary
Financials are weak overall: the income statement shows severe revenue volatility and persistent losses with negative EBIT/EBITDA margins; cash flow remains negative for both operating and free cash flow. The balance sheet is somewhat steadier with moderate leverage (debt-to-equity 0.62) but negative ROE indicates poor shareholder returns.
Income Statement
30
Negative
AnteoTech Ltd has experienced significant revenue volatility, with a notable decline in revenue growth rate of -277.78% in the most recent period. The company consistently reports negative net profit margins, with the latest at -6.98%, indicating ongoing profitability challenges. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Despite a high gross profit margin, the overall income statement performance is weak due to persistent losses.
Balance Sheet
40
Negative
The company's balance sheet shows a moderate debt-to-equity ratio of 0.62, suggesting manageable leverage. However, the return on equity is negative at -2.15%, indicating that the company is not generating returns on shareholder investments. The equity ratio is not explicitly calculated, but the declining stockholders' equity over time suggests weakening financial stability.
Cash Flow
35
Negative
AnteoTech Ltd's cash flow statement reveals negative operating and free cash flows, with a slight improvement in free cash flow growth rate at -12.83%. The operating cash flow to net income ratio is negative, highlighting cash flow challenges. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is somewhat aligned with net income, but overall cash flow performance remains weak.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.06M968.88K460.40K365.72K760.88K898.07K
Gross Profit2.06M968.88K460.40K365.72K760.88K898.07K
EBITDA-4.19M-7.96M-11.57M-12.35M-12.07M-7.18M
Net Income-4.48M-6.76M-8.88M-12.65M-10.72M-6.22M
Balance Sheet
Total Assets6.45M6.45M9.38M5.36M15.26M23.68M
Cash, Cash Equivalents and Short-Term Investments2.34M2.34M5.03M2.72M10.10M21.39M
Total Debt1.96M1.96M2.31M1.31M1.03M1.28M
Total Liabilities3.30M3.30M4.08M2.99M2.91M2.56M
Stockholders Equity3.15M3.15M5.31M2.38M12.36M21.11M
Cash Flow
Free Cash Flow-3.72M-6.05M-7.58M-8.77M-11.77M-4.76M
Operating Cash Flow-3.54M-5.83M-6.52M-8.08M-8.65M-4.55M
Investing Cash Flow-174.87K-174.87K-1.06M-690.83K-3.12M-213.07K
Financing Cash Flow3.32M3.32M9.89M1.39M482.29K22.94M

AnteoTech Ltd Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.02
Price Trends
50DMA
0.02
Negative
100DMA
0.02
Negative
200DMA
0.02
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
<0.01
Positive
STOCH
-2.98
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ADO, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at <0.01 is Positive, neither overbought nor oversold. The STOCH value of -2.98 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ADO.

AnteoTech Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
53
Neutral
AU$172.17M-17.08-41.51%-40.74%-21.21%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
AU$77.81M-8.13-49.72%10.78%
46
Neutral
AU$83.11M-7.74-138.54%16.61%
44
Neutral
AU$33.06M-9.09-143.71%306.88%
41
Neutral
AU$80.94M-8.11-71.87%7.65%-19.13%
40
Underperform
AU$40.14M-5.20-159.86%110.44%35.90%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:ADO
AnteoTech Ltd
0.01
>-0.01
-18.75%
AU:CYP
Cynata Therapeutics Limited
0.35
0.10
42.86%
AU:PTX
Prescient Therapeutics Limited
0.07
0.02
48.00%
AU:SPL
Starpharma Holdings Limited
0.41
0.31
310.00%
AU:AVE
Avecho Biotechnology Limited
0.01
0.00
0.00%
AU:PIQ
Proteomics International Laboratories Ltd.
0.49
-0.15
-23.44%

AnteoTech Ltd Corporate Events

AnteoTech Issues 138 Million Unlisted Options as Part of Previously Announced Transaction
Feb 4, 2026

AnteoTech Ltd has announced the issue of 138,206,230 unlisted options with an exercise price of 3.5 cents and an expiry date of 31 January 2028. The options, which form part of a previously flagged transaction and are not intended to be quoted on the ASX, represent a significant potential source of future equity and may dilute existing shareholders if exercised, while providing the company with additional capital-raising flexibility.

The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.

AnteoTech Files Cleansing Notice for Share and Option Placement
Feb 4, 2026

AnteoTech has issued 245.7 million new shares and 138.2 million listed options under its 27 January placement, with the securities released without a prospectus under section 708A and accompanied by confirmation of ongoing Corporations Act compliance and absence of excluded information; the cleansing notice clears the way for secondary trading, signalling continued execution of the company’s capital-raising plans to support its advanced materials strategy.

The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.

AnteoTech Boosts Cash Runway as Battery and Life Sciences Pipelines Advance
Jan 29, 2026

AnteoTech’s latest quarterly update highlights a strategic push to expand its sales pipeline and enter new markets through joint development and sales partnerships, alongside a strengthened balance sheet following a A$3.5 million capital raise completed in January 2026. In advanced battery technologies, the company signed a Joint Development and Sales Agreement with US-based Black Diamond Structures for a combined Anteo X™/Molecular Rebar™ CNT dispersion product with customer trials beginning in February, achieved a tenfold scale-up of Ultranode™ anode material for Wyon AG’s commercial cell evaluations, hit a new Ultranode™ X performance milestone of more than 1,000 cycles at 80% capacity retention, dispatched global samples of its new Anteo S separator, and is negotiating two Ultranode™ 95 JDAs with battery manufacturers supplying the US defence drone sector and other markets. In life sciences, AnteoTech secured a US$185,000 AnteoBind™ order from Serum Institute of India, gained additional Japanese sales, initiated evaluations of AnteoBind™-activated ELISA plates and a potential CLIA product development program with a major global life sciences company, and generated comparative data showing its AnteoBind™ NXT chemistry can cut antibody usage sixfold versus Tosyl chemistry while reducing non-specific binding. The company ended the quarter with A$1.4 million cash and no debt, and a pro-forma A$4.9 million post-raise, which it expects—together with revenue and an R&D rebate—to fund operations through calendar 2026, while it restructures its finance leadership and intensifies efforts to convert its expanded opportunity pipeline into sales across both its battery and diagnostics businesses.

The most recent analyst rating on (AU:ADO) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.

AnteoTech Names Scott Waddell Interim CFO and Company Secretary
Jan 28, 2026

AnteoTech Limited has appointed Scott Waddell as interim chief financial officer and company secretary, effective 2 February 2026, bringing three decades of corporate finance experience across multiple resource companies to the Brisbane-based advanced materials specialist. Waddell’s extensive background in leading finance teams, overseeing global finance and governance functions, and managing business development and M&A activities is expected to bolster AnteoTech’s financial stewardship and corporate governance as it continues to commercialise its battery and life sciences technologies in competitive global markets.

The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.

AnteoTech Plans Dual Tranche Options Issue to Bolster Capital Flexibility
Jan 27, 2026

AnteoTech Ltd has announced a proposed issue of securities via a placement, comprising a maximum of 15,356,249 new unlisted options with an exercise price of 3.5 cents and an expiry date of 31 January 2028, along with 15,356,249 options under existing code ADOO expiring 31 May 2026. The issuance, scheduled for 3 February 2026, is designed to expand the company’s option pool and may provide additional future capital if exercised, potentially affecting the capital structure and dilution for existing shareholders while supporting the company’s funding flexibility on the ASX.

The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.

AnteoTech Plans Major Equity and Options Issue to Bolster Capital Base
Jan 27, 2026

AnteoTech Ltd has announced a proposed placement or similar issue of up to 245,699,993 ordinary fully paid shares and 245,699,992 options, comprising 122,849,996 new unlisted options with a 3.5 cent exercise price expiring 31 January 2028 and 122,849,996 options expiring 31 May 2026. The issue, scheduled for 3 February 2026, represents a significant capital-raising and balance sheet initiative that will expand the company’s securities on issue, with potential dilution for existing shareholders but added optionality and future funding flexibility for the company as it pursues its strategic and operational objectives.

The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.

AnteoTech Raises A$3.5m to Fast-Track Life Sciences and Battery Tech Commercialisation
Jan 27, 2026

AnteoTech Ltd has raised A$3.5 million via a discounted share placement to institutional and professional investors, boosting its pro-forma cash balance to A$6.6 million and issuing free attaching listed and unlisted options as part of the offer. The funds will be used to accelerate the global commercialisation of its Life Sciences and Advanced Battery Technology products, support revenue growth initiatives, and advance strategic partnerships, including converting current customer trials into commercial supply agreements, entering the US market with a joint battery product developed with Black Diamond Structures, progressing EV-sector discussions around its Ultranode X technology, and driving new diagnostics customer wins and product development, particularly in India.

The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.

AnteoTech Shares Halted Pending Announcement of Material Capital Raising
Jan 21, 2026

AnteoTech Ltd has requested and been granted a trading halt on its shares by the ASX, effective from 22 January 2026, while it prepares a market announcement regarding a material capital raising. The halt will remain in place until either the company releases the capital-raising announcement or normal trading resumes on 27 January 2026, signalling that AnteoTech is moving to secure significant new funding, which could have implications for its capital structure and existing shareholders once details are disclosed.

The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.

AnteoTech Advances Ultranode and Anteo Product Suite as Drone Battery Demand Surges
Jan 18, 2026

AnteoTech has reported six‑month strategic progress for its Advanced Battery Technologies unit, highlighting rising commercial traction for its Ultranode™ 95 high‑silicon anode technology in the drone and defence sectors, with two non‑exclusive joint development agreements under negotiation with US‑ and Europe‑focused drone battery manufacturers. The company is expanding global sampling and validation of Ultranode™ 95 and Anteo X™ in the unmanned aerial systems market, responding to growing customer demand across the US, South Korea and Europe, while also launching its new Anteo S separator coating, completing a co‑developed carbon nanotube dispersion product with Black Diamond Structures ahead of customer trials, and advancing Ultranode™ 70 testing with Wyon AG—moves that collectively deepen its multi‑product pipeline and position AnteoTech to convert technical evaluations into commercial agreements in a rapidly growing drone battery market.

The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.

AnteoTech CFO and Company Secretary Andrew Cook Resigns
Jan 8, 2026

AnteoTech Ltd has announced the resignation of Andrew Cook from his dual roles as Chief Financial Officer and Company Secretary, as he departs to pursue other business interests. The board has commenced a process to identify his successor and has committed to an orderly transition under his existing employment terms, with further updates on interim and permanent arrangements to follow, signalling a period of financial and governance reshaping that stakeholders will watch closely given his central role in the company’s corporate and reporting functions.

The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.

AnteoTech Wins Serum Institute Order as Life Sciences Pipeline Accelerates
Dec 28, 2025

AnteoTech has secured a US$185,000 AnteoBind order from the Serum Institute of India under its five-year supply agreement, with shipment set for early January 2026, while simultaneously deepening the relationship through SII’s evaluation of a new AnteoBind-activated ELISA plate prototype targeting a market that accounts for roughly 40% of the global immunoassay segment. The company reports growing momentum in its Life Sciences business, including approximately AU$70,000 in new sales to Japanese customers, a sharp increase in AnteoBind NXT evaluations across major global markets, re-engagement with large life sciences players on joint CLIA and ELISA product development, and a strategic shift from additive supplier to core-ingredient provider, supported by recent peer-reviewed publications and expanded commercial activity in India, positioning AnteoTech to tap into the sizeable and fast-growing CLIA and ELISA markets in 2026 and beyond.

The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.

AnteoTech Ltd Advances High Silicon Anode Performance
Dec 11, 2025

AnteoTech Ltd has presented an update on its business activities, specifically highlighting advancements in maximizing high silicon anode performance. This development is significant for the company as it could enhance its position in the energy storage sector, potentially leading to improved operational efficiencies and market competitiveness.

The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.

AnteoTech Announces Director’s Change in Securities Holdings
Nov 28, 2025

AnteoTech Ltd has announced a change in the interests of its director, Glenda McLoughlin, involving the acquisition of 7,500,000 unlisted options and the expiry of 5,000,000 unlisted options. This adjustment in the director’s securities holdings reflects ongoing strategic decisions within the company, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.

AnteoTech Ltd Issues 42.5 Million Unquoted Options to Boost Growth
Nov 28, 2025

AnteoTech Ltd has announced the issuance of 42.5 million unquoted options, exercisable at $0.0375, with expiration dates in 2028 and 2029. This strategic move could potentially enhance the company’s financial flexibility and strengthen its market position by providing additional capital for growth and development.

The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.

AnteoTech Ltd Secures Strong Shareholder Support at 2025 AGM
Nov 26, 2025

AnteoTech Ltd announced the results of its 2025 Annual General Meeting, where all resolutions were passed by poll. Notably, less than 25% of votes were against the adoption of the 2025 remuneration report, eliminating the need to consider contingent resolution 6. This outcome reflects strong shareholder support and may positively impact AnteoTech’s governance and strategic initiatives, reinforcing its position in the advanced materials industry.

AnteoTech Ltd Reports Strategic Progress and Revenue Growth at 2025 AGM
Nov 25, 2025

AnteoTech Ltd’s 2025 AGM highlighted strategic advancements and operational restructuring under new leadership. The company reported significant progress in its Life Sciences division with the launch of AnteoBind NXT™ and a renewed agreement with the Serum Institute of India, resulting in a 110% revenue increase. In Advanced Battery Technologies, AnteoTech’s Ultranode™ X formulation achieved a major milestone, enhancing its competitiveness in the lithium-ion battery market. The company also expanded its customer engagement and entered a joint development agreement to strengthen its position in the global battery supply chain.

AnteoTech Achieves Milestone with Ultranode™ X Anode for EVs and eVTOLs
Nov 17, 2025

AnteoTech Ltd has announced a significant milestone with its Ultranode™ X anode, achieving over 1,000 charge/discharge cycles at 80% capacity retention. This development positions AnteoTech as a competitive player in the EV and eVTOL markets, offering a cost-effective and scalable anode technology. The achievement is expected to accelerate customer and partnership discussions, leveraging the use of micron-sized silicon materials that are less costly and more environmentally friendly compared to traditional composites. This advancement comes at a critical time as global supply chains face challenges, particularly with recent export restrictions from China, highlighting AnteoTech’s strategic advantage in providing trade restriction-independent solutions.

AnteoTech Scales Up Ultranode™ 70 Production for Wyon AG
Nov 12, 2025

AnteoTech Ltd has achieved a significant milestone by scaling up the production of its Ultranode™ 70 silicon anode for Wyon AG, a Swiss battery manufacturer. This development marks a crucial step in the commercialisation of AnteoTech’s technology, as it prepares for performance evaluations by Wyon. The successful integration of Ultranode™ 70 is expected to enhance energy capacity and battery life, potentially leading to a commercial supply agreement with Wyon, thereby strengthening AnteoTech’s position in the consumer battery market.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 05, 2026